Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Eric K Rowinsky is Director at Biogen. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 11, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
2
Eric K Rowinsky bought shares on the open market in 2017, 2023 and 2024, and has not bought since 2024 across 3 companies. Sales in 4 of the 15 years since 2012.
Eric K Rowinsky reported 3 open-market purchases and 12 sales since 2012; purchases in 3 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $101K1×1 trade | — |
| 2023 | $10K1×1 trade | — |
| 2021 | — | $127K5×5 trades |
| 2017 | $7.7K1×1 trade | — |
| 2015 | — | $10.5M4×4 trades |
| 2014 | — | $626K1×1 trade |
| 2012 | — | $1.51M2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
BiogenBIIB
Jun 9, 20261,505disclosed Jun 11
DetailsOfficial recordVerastemVSTM
May 21, 202636Kdisclosed May 26
DetailsOfficial recordAs of the latest filing on , Eric K Rowinsky reported holding 25,844 shares of Biogen (BIIB), worth about $6.5M at the last close of $251 (Nov 18, 2026). Holdings are also on file at Verastem (VSTM); together they are worth about $6.86M.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Biogen BIIB | 25,844 | 26K direct | $251 | $6.5M | Jun 9, 2026 |
| Verastem VSTM | 52,666 | 53K direct | $7 | $362K | May 21, 2026 |
Is this Eric K Rowinsky’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jun 9, 2026, Eric K Rowinsky reported holding 25,844 shares of Biogen (BIIB). At the last close of $251 on Nov 18, 2026, that is about $6.5M. This is the stake disclosed in filings, not a net worth.
No public filing gives Eric K Rowinsky's net worth. What SEC Form 4 shows is the stock stake: 25,844 shares of Biogen (BIIB), about $6.5M at the last close, plus holdings in 1 other company, about $6.86M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Eric K Rowinsky bought shares on the open market in 2017, 2023 and 2024, and has not bought since 2024 across 3 companies. Sales in 4 of the 15 years since 2012.
In SEC filings since 2012: the latest open-market purchase is from 2024; the latest open-market sale is from 2021.
3 companies: Biogen (BIIB, 2012–2024), Fortress Biotech (FBIO, 2021–2023), Verastem (VSTM, 2017).
Eric K Rowinsky reported 1 open-market purchase and 7 sales here, 2012 to 2024.
Eric K Rowinsky reported 1 open-market purchase and 5 sales here, 2021 to 2023.
Eric K Rowinsky reported 1 open-market purchase and 0 sales here, 2017.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.